GSN and Alzheimer disease: Interestingly, one of the two proteins identified as putative biomarkers by these “shotgun” proteomic approaches (GSN) was validated by ELISA and the results showed a clear tendency of decreased gelsolin concentration in DLB-EVs compared to controls-EVs and, importantly, to AD patients.